InvestorsHub Logo
Followers 5
Posts 519
Boards Moderated 0
Alias Born 01/05/2016

Re: None

Monday, 12/17/2018 2:10:39 PM

Monday, December 17, 2018 2:10:39 PM

Post# of 232321
I read earlier today that AbbVie (ABBV) recently stopped their Rova-T phase 3 study for cancer treatment. The IDMC recommended stoppage because when compared to the control arm of the study, the Rova-T arm had a shorter survival rate.

Rova-T was added to ABBV’s portfolio following a $5.8 billion acquisition in 2016.

Just shows the type of money BP spends yearly to acquire possible treatments, many of which fail and are never approved.

Hey ABBV...check out Leronlimab in several months! Oh and bring your checkbook.

Things should get interesting shortly!

All IMO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News